The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study

被引:2
作者
Ak, Muzeyyen Aslaner [1 ]
Sahip, Birsen [1 ]
Geduk, Ayfer [2 ]
Ucar, Mehmer Ali [3 ]
Kale, Hacer [4 ]
Hacibekiroglu, Tugba [5 ]
Polat, Merve Gokcen [2 ]
Kalpakci, Yasin [5 ]
Bolaman, Ali Zahit [4 ]
Guvenc, Birol [3 ]
Ertop, Sehmus [1 ]
机构
[1] Zonguldak Bulent Ecevit Univ, Fac Med, Dept Hematol, TR-67100 Incivez, Zonguldak, Turkey
[2] Kocaeli Univ, Dept Hematol, Fac Med, Kocaeli, Turkey
[3] Cukurova Univ, Dept Hematol, Fac Med, Adana, Turkey
[4] Adnan Menderes Univ, Dept Hematol, Fac Med, Aydin, Turkey
[5] Sakarya Training & Res Hosp, Dept Hematol, Sakarya, Turkey
关键词
Myelodysplastic syndrome; Low-risk-intermediate-1-risk; Epoetin alfa; Darbepoetin alfa; Treatment response; ERYTHROPOIETIN-STIMULATING AGENTS; PHASE-II; PREDICTIVE FACTORS; RESPONSE RATE; ANEMIA; TRIAL; SAFETY; DIAGNOSIS; MODEL;
D O I
10.1007/s12288-021-01458-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean +/- SD 8.68 +/- 1.0 g/dL at baseline vs. 9.83 +/- 1.45, 9.99 +/- 1.55, 10.24 +/- 1.77 and 10.2 +/- 1.5 g/dL, respectively) and darbepoetin alfa (8.83 +/- 1.09 g/dL at baseline vs. 9.62 +/- 1.37, 9.78 +/- 1.49, 9.9 +/- 1.39 and 10.1 +/- 1.5 g/dL, respectively) groups (p < 0.001 for each). Transfusion need significantly decreased from baseline at each study visit in the epoetin alfa group (p < 0.001) and only at the 12th month visit (p < 0.001) in the darbepoetin alfa group. Hemoglobin levels or transfusion need was similar between treatment groups. Overall, 12-month response rate was 58.1% for epoetin alfa and 41.9% for darbepoetin alfa, with no significant difference between treatment groups, whereas higher response rate was noted within the first three months (62.7%) compared to next 9 months (ranged 44.4-60%) of treatment in the epoetin alfa group (p ranged 0.002 to < 0.001). This real-life retrospective study revealed similar efficacy of epoetin alfa and darbepoetin alfa among low risk or intermediate-1 risk MDS patients with no difference in treatment response between treatment groups, whereas a likelihood of earlier treatment response in the epoetin alfa group.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 37 条
  • [1] Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes
    Cortesao, Emlia
    Tenreiro, Rita
    Ramos, Sofia
    Pereira, Marta
    Cesar, Paula
    Carda, Jose P.
    Gomes, Marilia
    Rito, Luis
    Magalhaes, Emlia
    Goncalves, Ana C.
    Silva, Nuno C. e
    Geraldes, Catarina
    Pereira, Amelia
    Ribeiro, Leticia
    Nascimento Costa, Jose M.
    Sarmento Ribeiro, Ana B.
    [J]. ACTA MEDICA PORTUGUESA, 2015, 28 (06): : 720 - 725
  • [2] Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines
    Davidoff, Amy J.
    Weiss, Sheila R.
    Baer, Maria R.
    Ke, Xuehua
    Hendrick, Franklin
    Zeidan, Amer
    Gore, Steven D.
    [J]. LEUKEMIA RESEARCH, 2013, 37 (06) : 675 - 680
  • [3] Variations in erythropoiesis-stimulating agent administration intransfusion-dependent myelodysplastic syndromes impact response
    Duong, Vu H.
    Baer, Maria R.
    Hendrick, Franklin
    Weiss, Sheila R.
    Sato, Masayo
    Zeidan, Amer M.
    Gore, Steven D.
    Davidoff, Amy J.
    [J]. LEUKEMIA RESEARCH, 2015, 39 (06) : 586 - 591
  • [4] Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Fenaux, P.
    Haase, D.
    Sanz, G. F.
    Santini, V.
    Buske, C.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 : 57 - 69
  • [5] A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
    Fenaux, Pierre
    Santini, Valeria
    Spiriti, Maria Antonietta Aloe
    Giagounidis, Aristoteles
    Schlag, Rudolf
    Radinoff, Atanas
    Gercheva-Kyuchukova, Liana
    Anagnostopoulos, Achilles
    Oliva, Esther Natalie
    Symeonidis, Argiris
    Berger, Mathilde Hunault
    Goetze, Katharina S.
    Potamianou, Anna
    Haralampiev, Hari
    Wapenaar, Robert
    Milionis, Iordanis
    Platzbecker, Uwe
    [J]. LEUKEMIA, 2018, 32 (12) : 2648 - 2658
  • [6] Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
    Gabrilove, Janice
    Paquette, Ronald
    Lyons, Roger M.
    Mushtaq, Chaudhry
    Sekeres, Mikkael A.
    Tomita, Dianne
    Dreiling, Lyndah
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) : 379 - 393
  • [7] Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil
    Gadelha Moura, Anna Thawanny
    Duarte, Fernando Barroso
    Barbosa, Maritza Cavalcante
    de Jesus dos Santos, Talyta Ellen
    Goncalves Lemes, Romelia Pinheiro
    [J]. CLINICS, 2019, 74
  • [8] Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols
    Gascon, Pere
    Krendyukov, Andriy
    Mathieson, Nicola
    Aapro, Matti
    [J]. LEUKEMIA RESEARCH, 2019, 81 : 35 - 42
  • [9] A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
    Gotlib, Jason
    Lavori, Philip
    Quesada, Sylvia
    Stein, Richard S.
    Shahnia, Shahin
    Greenberg, Peter L.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (01) : 15 - 20
  • [10] International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P
    Cox, C
    LeBeau, MM
    Fenaux, P
    Morel, P
    Sanz, G
    Sanz, M
    Vallespi, T
    Hamblin, T
    Oscier, D
    Ohyashiki, K
    Toyama, K
    Aul, C
    Mufti, G
    Bennett, J
    [J]. BLOOD, 1997, 89 (06) : 2079 - 2088